Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators
Without cystic fibrosis transmembrane conductance regulator-mediated (CFTR-mediated) HCO3- secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months...
Gespeichert in:
Veröffentlicht in: | The Journal of clinical investigation 2021-08, Vol.131 (16), p.1-11 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 11 |
---|---|
container_issue | 16 |
container_start_page | 1 |
container_title | The Journal of clinical investigation |
container_volume | 131 |
creator | Rehman, Tayyab Karp, Philip H Tan, Ping Goodell, Brian J Pezzulo, Alejandro A Thurman, Andrew L Thornell, Ian M Durfey, Samantha L Duffey, Michael E Stoltz, David A McKone, Edward F Singh, Pradeep K Welsh, Michael J |
description | Without cystic fibrosis transmembrane conductance regulator-mediated (CFTR-mediated) HCO3- secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl-/HCO3- exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator-induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3- secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators. |
doi_str_mv | 10.1172/JCI150398 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8363270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2545599463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-b7d328c108584ebe09d216048c7d58abb43d729d7496601d07cede88f9530a3e3</originalsourceid><addsrcrecordid>eNpdkU1uFDEQhS0EIiGw4ALIEhuyaLDbv71BQiMCg0awCWvLbVdnHLrtYHcjzYY7cZGcCQ8TRoFVleSvnl_VQ-g5Ja8pVe2bT6s1FYR1-gE6pULoRrdMP7zXn6AnpVwTQjkX_DE6YZxK2TJyin6u4zDaabJzyjvsdnP6FiIUfPn5orn9hW30eL1pqMIQtzY6wPMWMAxDcNbtcBrqSJmDw0Pocyqh4DnbWCaY-loBuxT94uY_kxmulnH_D56SP3TlKXo02LHAs7t6hr5evL9cfWw2Xz6sV-82jeOEzU2vPGu1o0QLzaEH0vmWSsK1U15o2_ecedV2XvFOSkI9UQ48aD10ghHLgJ2htwfdm6WfwDuI1edobnKYbN6ZZIP59yWGrblKP4xmkrWKVIFXdwI5fV-gzGYKxcE41i3TUkwruBBdxyWr6Mv_0Ou05FjXq5TUSlIt94LnB8rVu5UMw9EMJWafqjmmWtkX990fyb8xst8fK58V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2568761860</pqid></control><display><type>article</type><title>Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Rehman, Tayyab ; Karp, Philip H ; Tan, Ping ; Goodell, Brian J ; Pezzulo, Alejandro A ; Thurman, Andrew L ; Thornell, Ian M ; Durfey, Samantha L ; Duffey, Michael E ; Stoltz, David A ; McKone, Edward F ; Singh, Pradeep K ; Welsh, Michael J</creator><creatorcontrib>Rehman, Tayyab ; Karp, Philip H ; Tan, Ping ; Goodell, Brian J ; Pezzulo, Alejandro A ; Thurman, Andrew L ; Thornell, Ian M ; Durfey, Samantha L ; Duffey, Michael E ; Stoltz, David A ; McKone, Edward F ; Singh, Pradeep K ; Welsh, Michael J</creatorcontrib><description>Without cystic fibrosis transmembrane conductance regulator-mediated (CFTR-mediated) HCO3- secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl-/HCO3- exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator-induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3- secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators.</description><identifier>ISSN: 1558-8238</identifier><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI150398</identifier><identifier>PMID: 34166230</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject><![CDATA[Acids ; Aminophenols - administration & dosage ; Benzodioxoles - administration & dosage ; Bicarbonates - metabolism ; Biomedical research ; Birth ; Cells, Cultured ; Chlorides ; Cystic fibrosis ; Cystic Fibrosis - drug therapy ; Cystic Fibrosis - immunology ; Cystic Fibrosis - physiopathology ; Cystic Fibrosis Transmembrane Conductance Regulator - drug effects ; Cystic Fibrosis Transmembrane Conductance Regulator - genetics ; Cystic Fibrosis Transmembrane Conductance Regulator - metabolism ; Cytokines ; Drug Combinations ; Gene expression ; Humans ; Hydrogen-Ion Concentration ; Hypotheses ; Indoles - administration & dosage ; Infant ; Infant, Newborn ; Inflammation ; Interleukin 17 ; Interleukin-17 - administration & dosage ; Interleukin-17 - metabolism ; Ion Transport ; Mutation ; Neonates ; pH effects ; Pyrazoles - administration & dosage ; Pyridines - administration & dosage ; Quinolines - administration & dosage ; Respiratory function ; Respiratory Mucosa - drug effects ; Respiratory Mucosa - immunology ; Respiratory Mucosa - metabolism ; Respiratory tract ; Respiratory tract diseases ; Sulfate Transporters - genetics ; Sulfate Transporters - metabolism ; Tumor Necrosis Factor-alpha - administration & dosage ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-α]]></subject><ispartof>The Journal of clinical investigation, 2021-08, Vol.131 (16), p.1-11</ispartof><rights>Copyright American Society for Clinical Investigation Aug 2021</rights><rights>2021 American Society for Clinical Investigation 2021 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-b7d328c108584ebe09d216048c7d58abb43d729d7496601d07cede88f9530a3e3</citedby><cites>FETCH-LOGICAL-c403t-b7d328c108584ebe09d216048c7d58abb43d729d7496601d07cede88f9530a3e3</cites><orcidid>0000-0002-1646-6206 ; 0000-0002-7777-4165 ; 0000-0002-7949-1150 ; 0000-0001-7792-201X ; 0000-0001-7544-5109 ; 0000-0003-0893-9015 ; 0000-0001-5535-2925</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363270/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363270/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34166230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rehman, Tayyab</creatorcontrib><creatorcontrib>Karp, Philip H</creatorcontrib><creatorcontrib>Tan, Ping</creatorcontrib><creatorcontrib>Goodell, Brian J</creatorcontrib><creatorcontrib>Pezzulo, Alejandro A</creatorcontrib><creatorcontrib>Thurman, Andrew L</creatorcontrib><creatorcontrib>Thornell, Ian M</creatorcontrib><creatorcontrib>Durfey, Samantha L</creatorcontrib><creatorcontrib>Duffey, Michael E</creatorcontrib><creatorcontrib>Stoltz, David A</creatorcontrib><creatorcontrib>McKone, Edward F</creatorcontrib><creatorcontrib>Singh, Pradeep K</creatorcontrib><creatorcontrib>Welsh, Michael J</creatorcontrib><title>Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Without cystic fibrosis transmembrane conductance regulator-mediated (CFTR-mediated) HCO3- secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl-/HCO3- exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator-induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3- secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators.</description><subject>Acids</subject><subject>Aminophenols - administration & dosage</subject><subject>Benzodioxoles - administration & dosage</subject><subject>Bicarbonates - metabolism</subject><subject>Biomedical research</subject><subject>Birth</subject><subject>Cells, Cultured</subject><subject>Chlorides</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Cystic Fibrosis - immunology</subject><subject>Cystic Fibrosis - physiopathology</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - drug effects</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - genetics</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - metabolism</subject><subject>Cytokines</subject><subject>Drug Combinations</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hypotheses</subject><subject>Indoles - administration & dosage</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Inflammation</subject><subject>Interleukin 17</subject><subject>Interleukin-17 - administration & dosage</subject><subject>Interleukin-17 - metabolism</subject><subject>Ion Transport</subject><subject>Mutation</subject><subject>Neonates</subject><subject>pH effects</subject><subject>Pyrazoles - administration & dosage</subject><subject>Pyridines - administration & dosage</subject><subject>Quinolines - administration & dosage</subject><subject>Respiratory function</subject><subject>Respiratory Mucosa - drug effects</subject><subject>Respiratory Mucosa - immunology</subject><subject>Respiratory Mucosa - metabolism</subject><subject>Respiratory tract</subject><subject>Respiratory tract diseases</subject><subject>Sulfate Transporters - genetics</subject><subject>Sulfate Transporters - metabolism</subject><subject>Tumor Necrosis Factor-alpha - administration & dosage</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-α</subject><issn>1558-8238</issn><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkU1uFDEQhS0EIiGw4ALIEhuyaLDbv71BQiMCg0awCWvLbVdnHLrtYHcjzYY7cZGcCQ8TRoFVleSvnl_VQ-g5Ja8pVe2bT6s1FYR1-gE6pULoRrdMP7zXn6AnpVwTQjkX_DE6YZxK2TJyin6u4zDaabJzyjvsdnP6FiIUfPn5orn9hW30eL1pqMIQtzY6wPMWMAxDcNbtcBrqSJmDw0Pocyqh4DnbWCaY-loBuxT94uY_kxmulnH_D56SP3TlKXo02LHAs7t6hr5evL9cfWw2Xz6sV-82jeOEzU2vPGu1o0QLzaEH0vmWSsK1U15o2_ecedV2XvFOSkI9UQ48aD10ghHLgJ2htwfdm6WfwDuI1edobnKYbN6ZZIP59yWGrblKP4xmkrWKVIFXdwI5fV-gzGYKxcE41i3TUkwruBBdxyWr6Mv_0Ou05FjXq5TUSlIt94LnB8rVu5UMw9EMJWafqjmmWtkX990fyb8xst8fK58V</recordid><startdate>20210816</startdate><enddate>20210816</enddate><creator>Rehman, Tayyab</creator><creator>Karp, Philip H</creator><creator>Tan, Ping</creator><creator>Goodell, Brian J</creator><creator>Pezzulo, Alejandro A</creator><creator>Thurman, Andrew L</creator><creator>Thornell, Ian M</creator><creator>Durfey, Samantha L</creator><creator>Duffey, Michael E</creator><creator>Stoltz, David A</creator><creator>McKone, Edward F</creator><creator>Singh, Pradeep K</creator><creator>Welsh, Michael J</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1646-6206</orcidid><orcidid>https://orcid.org/0000-0002-7777-4165</orcidid><orcidid>https://orcid.org/0000-0002-7949-1150</orcidid><orcidid>https://orcid.org/0000-0001-7792-201X</orcidid><orcidid>https://orcid.org/0000-0001-7544-5109</orcidid><orcidid>https://orcid.org/0000-0003-0893-9015</orcidid><orcidid>https://orcid.org/0000-0001-5535-2925</orcidid></search><sort><creationdate>20210816</creationdate><title>Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators</title><author>Rehman, Tayyab ; Karp, Philip H ; Tan, Ping ; Goodell, Brian J ; Pezzulo, Alejandro A ; Thurman, Andrew L ; Thornell, Ian M ; Durfey, Samantha L ; Duffey, Michael E ; Stoltz, David A ; McKone, Edward F ; Singh, Pradeep K ; Welsh, Michael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-b7d328c108584ebe09d216048c7d58abb43d729d7496601d07cede88f9530a3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acids</topic><topic>Aminophenols - administration & dosage</topic><topic>Benzodioxoles - administration & dosage</topic><topic>Bicarbonates - metabolism</topic><topic>Biomedical research</topic><topic>Birth</topic><topic>Cells, Cultured</topic><topic>Chlorides</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Cystic Fibrosis - immunology</topic><topic>Cystic Fibrosis - physiopathology</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - drug effects</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - genetics</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - metabolism</topic><topic>Cytokines</topic><topic>Drug Combinations</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hypotheses</topic><topic>Indoles - administration & dosage</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Inflammation</topic><topic>Interleukin 17</topic><topic>Interleukin-17 - administration & dosage</topic><topic>Interleukin-17 - metabolism</topic><topic>Ion Transport</topic><topic>Mutation</topic><topic>Neonates</topic><topic>pH effects</topic><topic>Pyrazoles - administration & dosage</topic><topic>Pyridines - administration & dosage</topic><topic>Quinolines - administration & dosage</topic><topic>Respiratory function</topic><topic>Respiratory Mucosa - drug effects</topic><topic>Respiratory Mucosa - immunology</topic><topic>Respiratory Mucosa - metabolism</topic><topic>Respiratory tract</topic><topic>Respiratory tract diseases</topic><topic>Sulfate Transporters - genetics</topic><topic>Sulfate Transporters - metabolism</topic><topic>Tumor Necrosis Factor-alpha - administration & dosage</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rehman, Tayyab</creatorcontrib><creatorcontrib>Karp, Philip H</creatorcontrib><creatorcontrib>Tan, Ping</creatorcontrib><creatorcontrib>Goodell, Brian J</creatorcontrib><creatorcontrib>Pezzulo, Alejandro A</creatorcontrib><creatorcontrib>Thurman, Andrew L</creatorcontrib><creatorcontrib>Thornell, Ian M</creatorcontrib><creatorcontrib>Durfey, Samantha L</creatorcontrib><creatorcontrib>Duffey, Michael E</creatorcontrib><creatorcontrib>Stoltz, David A</creatorcontrib><creatorcontrib>McKone, Edward F</creatorcontrib><creatorcontrib>Singh, Pradeep K</creatorcontrib><creatorcontrib>Welsh, Michael J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rehman, Tayyab</au><au>Karp, Philip H</au><au>Tan, Ping</au><au>Goodell, Brian J</au><au>Pezzulo, Alejandro A</au><au>Thurman, Andrew L</au><au>Thornell, Ian M</au><au>Durfey, Samantha L</au><au>Duffey, Michael E</au><au>Stoltz, David A</au><au>McKone, Edward F</au><au>Singh, Pradeep K</au><au>Welsh, Michael J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2021-08-16</date><risdate>2021</risdate><volume>131</volume><issue>16</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>1558-8238</issn><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>Without cystic fibrosis transmembrane conductance regulator-mediated (CFTR-mediated) HCO3- secretion, airway epithelia of newborns with cystic fibrosis (CF) produce an abnormally acidic airway surface liquid (ASL), and the decreased pH impairs respiratory host defenses. However, within a few months of birth, ASL pH increases to match that in non-CF airways. Although the physiological basis for the increase is unknown, this time course matches the development of inflammation in CF airways. To learn whether inflammation alters CF ASL pH, we treated CF epithelia with TNF-α and IL-17 (TNF-α+IL-17), 2 inflammatory cytokines that are elevated in CF airways. TNF-α+IL-17 markedly increased ASL pH by upregulating pendrin, an apical Cl-/HCO3- exchanger. Moreover, when CF epithelia were exposed to TNF-α+IL-17, clinically approved CFTR modulators further alkalinized ASL pH. As predicted by these results, in vivo data revealed a positive correlation between airway inflammation and CFTR modulator-induced improvement in lung function. These findings suggest that inflammation is a key regulator of HCO3- secretion in CF airways. Thus, they explain earlier observations that ASL pH increases after birth and indicate that, for similar levels of inflammation, the pH of CF ASL is abnormally acidic. These results also suggest that a non-cell-autonomous mechanism, airway inflammation, is an important determinant of the response to CFTR modulators.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>34166230</pmid><doi>10.1172/JCI150398</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1646-6206</orcidid><orcidid>https://orcid.org/0000-0002-7777-4165</orcidid><orcidid>https://orcid.org/0000-0002-7949-1150</orcidid><orcidid>https://orcid.org/0000-0001-7792-201X</orcidid><orcidid>https://orcid.org/0000-0001-7544-5109</orcidid><orcidid>https://orcid.org/0000-0003-0893-9015</orcidid><orcidid>https://orcid.org/0000-0001-5535-2925</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1558-8238 |
ispartof | The Journal of clinical investigation, 2021-08, Vol.131 (16), p.1-11 |
issn | 1558-8238 0021-9738 1558-8238 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8363270 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Acids Aminophenols - administration & dosage Benzodioxoles - administration & dosage Bicarbonates - metabolism Biomedical research Birth Cells, Cultured Chlorides Cystic fibrosis Cystic Fibrosis - drug therapy Cystic Fibrosis - immunology Cystic Fibrosis - physiopathology Cystic Fibrosis Transmembrane Conductance Regulator - drug effects Cystic Fibrosis Transmembrane Conductance Regulator - genetics Cystic Fibrosis Transmembrane Conductance Regulator - metabolism Cytokines Drug Combinations Gene expression Humans Hydrogen-Ion Concentration Hypotheses Indoles - administration & dosage Infant Infant, Newborn Inflammation Interleukin 17 Interleukin-17 - administration & dosage Interleukin-17 - metabolism Ion Transport Mutation Neonates pH effects Pyrazoles - administration & dosage Pyridines - administration & dosage Quinolines - administration & dosage Respiratory function Respiratory Mucosa - drug effects Respiratory Mucosa - immunology Respiratory Mucosa - metabolism Respiratory tract Respiratory tract diseases Sulfate Transporters - genetics Sulfate Transporters - metabolism Tumor Necrosis Factor-alpha - administration & dosage Tumor Necrosis Factor-alpha - metabolism Tumor necrosis factor-α |
title | Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A54%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammatory%20cytokines%20TNF-%CE%B1%20and%20IL-17%20enhance%20the%20efficacy%20of%20cystic%20fibrosis%20transmembrane%20conductance%20regulator%20modulators&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Rehman,%20Tayyab&rft.date=2021-08-16&rft.volume=131&rft.issue=16&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=1558-8238&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI150398&rft_dat=%3Cproquest_pubme%3E2545599463%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2568761860&rft_id=info:pmid/34166230&rfr_iscdi=true |